阿加曲班与巴曲酶治疗进展性脑梗死的疗效观察  

Effect Observation of the Treatment of Progressive Cerebral Infarction With Argatroban and Batroxobin

作　　者：丁琪[1] 陆耀军[1] 尤年兴[1] 

机构地区：[1]江苏省常熟市第二人民医院神经内科,215500

出　　处：《中国继续医学教育》2015年第24期176-177,共2页China Continuing Medical Education

摘　　要：目的观察巴曲酶及阿加曲班治疗急性进展性脑梗死的效果。方法收集150名急性进展性脑梗死患者,随机分为常规组,巴曲酶组、阿加曲班组,观察治疗前后生化指标及不良反应。结果经治疗,巴曲酶组有效率52.0%,阿加曲班组有效率为72.0%,都好于常规组28.0%,差异有统计学意义(P<0.05)。结论巴曲酶、阿加曲班治疗急性进展性脑梗死是安全有效的,阿加曲班更为有效。Objective To observe the effect of the treatment of acute progressive cerebral infarction acute progressive cerebral infarction. Methods 150 cases of acute progressive cerebral infarction patients into normal group, batroxobin group, argatroban observed reactions. Results Batroxobin group have efifciency 52.0%and argatroban group effective rate was 72.0%, signiifcantly better than the control group 28.0%, the difference was statistically signiifcant （P〈0.05）. Conclusion The treatment of acute progressive cerebral infarction is safe and effective.

关 键 词：急性进展性脑梗死 巴曲酶 阿加曲班 

分 类 号：R743.3[医药卫生—神经病学与精神病学]